ASTR.NS
Latest Trade
3,724.70INRChange
-85.50(-2.24%)Volume
80,950Today's Range
-
3,800.0052 Week Range
-
4,970.00As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
Previous Close | 3,810.20 |
|---|---|
Open | 3,790.00 |
Volume | 80,950 |
3M AVG Volume | 1.83 |
Today's High | 3,800.00 |
Today's Low | 3,710.00 |
52 Week High | 4,970.00 |
52 Week Low | 1,885.00 |
Shares Out (MIL) | 25.00 |
Market Cap (MIL) | 95,255.00 |
Forward P/E | -- |
Dividend (Yield %) | 0.05 |
Astrazeneca Pharma India Sept-Quarter Profit Rises
Astrazeneca Pharma India Commences Launch Of QTERN In India
Astrazeneca Pharma India Dec-Quarter Profit Falls
AstraZeneca Pharma India Limited is a global biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The Company operates through two segments: Healthcare and Clinical Trial. The Healthcare segment engages in the manufacture and sale of pharmaceutical products. The Clinical Trial segment renders clinical trial services on pharmaceutical products to its group companies. It has presence in over seven areas of healthcare, including diabetes, oncology, infection, local anesthesia and maternal healthcare. The principal products/services of the Company are Meronem and Brilinta/Axcer. Its pipeline includes products, such as AZD4076, MEDI6012, AZD2811, MEDI0680, selumetinib, anifrolumab and MEDI7510. Its brands include Crestor, Seloken XL, Meronem, Arimidex, Zoladex, Nexium and Brilinta.
Industry
Major Drugs
Contact Info
Ni 12Th Floor, Manyata Empassy Business
Park Rachenahalli,Outer Ring Rd Kr Puram
Hebbal
560045
India
+91.80.67748000
https://www.astrazeneca.com/country-sites/india.htmlExecutive Leadership
Darius Erach Udwadia
Non-Executive Independent Chairman of the Board
Rajesh Marwaha
Chief Financial Officer, Acting Compliance Officer, Whole Time Director
Pratap Rudra
Compliance Officer, Company Secretary
Gagan Singh Bedi
Managing Director, Director
Sanjay Murdeshwar
Managing Director, Director
Price To Earnings (TTM) | 117.23 |
|---|---|
Price To Sales (TTM) | 11.59 |
Price To Book (MRQ) | 23.52 |
Price To Cash Flow (TTM) | 95.50 |
Total Debt To Equity (MRQ) | 2.92 |
LT Debt To Equity (MRQ) | 2.21 |
Return on Investment (TTM) | 21.19 |
Return on Equity (TTM) | 11.89 |
AstraZeneca's <AZN.L> suspension of global trials of its experimental coronavirus vaccine after an illness in a study subject in Britain has cast doubt on prospects for an early rollout of one of the most advanced COVID-19 vaccines in development.
AstraZeneca has paused global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, denting the British drugmaker's shares on Wednesday as the move was seen as dimming prospects for an early rollout.
* ASTRAZENECA PHARMA INDIA - COMMENCED LAUNCH OF FDC OF DAPAGLIFLOZIN 10MG + SAXAGLIPTIN 5MG FILM COATED TABLETS IN INDIA Source text: (http://bit.ly/32jbu7G) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.